Online inquiry

IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methyl-CTP, 30 nt-poly(A))   (CAT#: GTTS-WQ13546MR)

This product GTTS-WQ13546MR is a type of mRNA having 30 nt poly(A) tail and modified with Cap 1 & 5-Methyl-CTP. It ecodes the monoclonal antibody that targets MCAM gene. The antibody can be applied in Psoriasis research.
Specifications
Product type mRNA
Modified bases 5-Methyl-CTP
5' Cap Cap 1
Species Humanized
RefSeq NM_006500.3
Applications Gene therapy research
Format Powder
Quantity 100 µg
Purification oligo-dT affinity purification
Target Gene
Gene ID 4162
UniProt ID P43121
Download
Download resources about mRNA therapeutics development to boost your research.
CUSTOMER REVIEWS and Q&As

There are currently no Customer reviews or questions for IVTScrip™ mRNA-Anti-MCAM, PRX-003(Cap 1, 5-Methyl-CTP, 30 nt-poly(A)) (GTTS-WQ13546MR). Click the button above to contact us or submit your feedback about this product.
See other products
CAT Product Name Product Type CDs
GTTS-WQ280MR IVTScrip™ mRNA-Anti-CD37, 177lu-DOTA-HH1(Cap 1, N1-Methylpseudo-UTP, 120 nt-poly(A)) mRNA 177lu-DOTA-HH1
GTTS-WQ12276MR IVTScrip™ mRNA-Anti-CD274, MSB-0010718C(Cap 1, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA MSB-0010718C
GTTS-WQ4202MR IVTScrip™ mRNA-Anti-IL2RA, BIIB019(Cap 1, N1-Methylpseudo-UTP, 30 nt-poly(A)) mRNA BIIB019
GTTS-WQ3648MR IVTScrip™ mRNA-Anti-FGFR2, BAY 1187982(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA BAY 1187982
GTTS-WQ6914MR IVTScrip™ mRNA-Anti-Alkaline phosphatase substitute, ENB-0040(Cap 1, 2-Thio-UTP, 120 nt-poly(A)) mRNA ENB-0040
GTTS-WQ11802MR IVTScrip™ mRNA-Anti-PDCD1, MK-3475(Cap 1, Pseudo-UTP, 120 nt-poly(A)) mRNA MK-3475
GTTS-WQ14369MR IVTScrip™ mRNA-Anti-TNF, r-hTBP-1(Cap 0, Pseudo-UTP, 120 nt-poly(A)) mRNA r-hTBP-1
GTTS-WQ8123MR IVTScrip™ mRNA-Anti-CD37, HH1(Cap 0, 5-Methyl-CTP & Pseudo-UTP, 120 nt-poly(A)) mRNA HH1
All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
webinar

EABR Nanoparticles as a Platform Technology for Hybrid mRNA Vaccine Development

November 20th, 2024, 2 PM–3 PM EST

REGISTER NOW